
Articles
-
1 month ago |
eyetube.net | I. Paul Singh
Innovations in Glaucoma: Procedural Pharmaceuticals I. Paul Singh, MD; and Steven R. Sarkisian Jr, MD Show Description + Steven R. Sarkisian Jr., MD, joins I. Paul Singh, MD, on Innovation Journal Club to discuss the impact of procedural pharmaceuticals on glaucoma management. Along with a review of a recent study on the topic, the two discuss how the advent of procedural pharmaceuticals enables a more proactive approach.
-
1 month ago |
healio.com | I. Paul Singh |Anthony DeFino |Christine Klimanskis
Read more ORLANDO — In this Healio Video Perspective from Telling It Like It Is, I. Paul Singh, MD, shares how Dextenza can decrease the topical drop burden of steroids and improve efficiency of ophthalmic surgery. According to Singh, Dextenza (dexamethasone ophthalmic insert 0.4 mg, Ocular Therapeutix) reduces the amount of time ophthalmologists spend on patient education and follow-up, as well as time spent in discussions with insurance companies and pharmacies.
-
2 months ago |
eyetube.net | I. Paul Singh |Carl D. Regillo
Innovations in AMD Therapy: Second-Generation Anti-VEGFs I. Paul Singh, MD; and Carl D. Regillo, MD Show Description + In this episode of Innovation Journal Club, Carl Regillo, MD, and I. Paul Singh, MD, discuss outcomes from phase 3 studies of faricimab-svoa (Vabysmo, Genentech) and aflibercept 8 mg (Eyelea HD, Regeneron) in neovascular AMD. According to Dr. Regillo, the data suggests that these agents achieve greater durability and a better drying effect than first-generation anti-VEGF drugs.
-
2 months ago |
healio.com | I. Paul Singh |Anthony DeFino |Christine Klimanskis
ORLANDO — In this Healio Video Perspective from Telling It Like It Is, I. Paul Singh, MD, discusses utilizing the “robust” portfolio of technologies and devices to shift to an interventional glaucoma mindset. While topical therapies often lead to patient noncompliance, new technologies empower ophthalmologist to “take control back to our hands as providers,” according to Singh.
-
Feb 12, 2025 |
healio.com | I. Paul Singh |Anthony DeFino |Christine Klimanskis
KOLOA, Hawaii — In this Healio Video Perspective from Hawaiian Eye 2025, I. Paul Singh, MD,discusses the AquaLumen, a subconjunctival bypass technology to lower IOP in patients with glaucoma. AquaLumen (PLU Ophthalmic) allows ophthalmologists to enter the anterior chamber through the sclera and create a tunnel for improved flow of fluid to the subconjunctival space.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →